

Data	Presentor	Title	Journal	Year	Vol	Page
2018/1/9	北之園英明	Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma	Oncotarget	2017	8	106527–106537
	波多智子	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation	N Engl J Med	2017	377	2433–2444
2018/1/23	クリクラ学生	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer	J Clin Oncol	2017	–	–
	長井一浩	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications	Blood	2018	131	247–262
2018/2/13	小林裕児	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation	Nature Medicine	2017	23	1055–1062
2018/2/20	クリクラ学生	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma	N Engl J Med	2018	378	518–528
	澤山靖	Post-Transplantation Lymphoproliferative Disorders in Adults	N Engl J Med	2018	378	549–562
2018/2/27	宮崎泰司	Clonal analysis of lineage fate in native haematopoiesis	Nature	2018	553	212–216
2018/3/6	塚田幸絵	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma	J Clin Oncol	2018	36	689–696
2018/3/13	小林裕児	Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma	Blood	2018	131	771–781
2018/3/20	北之園英明	cAMP induces cell apoptosis in multiple myeloma and overcomes bortezomib resistance	Am J Cancer Res	2018	8	16–29
	糸永英弘	Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy	Blood	2017	129	38–47
2018/3/27	田口正剛	Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells	Nature	2018	553	171–177
	佐藤信也	Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia	Leukemia	2018	–	–